.png){kind=icon}
Return
Atherosclerosis
.png){kind=icon}
PRE
AI
DOI：10.1038/s41572-019-0106-z.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Atherosclerosis, the formation of fibrofatty lesions in the artery wall, causes much morbidity and mortality worldwide, including most myocardial infarctions and many strokes, as well as disabling peripheral artery disease. Development of atherosclerotic lesions probably requires low-density lipoprotein, a particle that carries cholesterol through the blood. Other risk factors for atherosclerosis and its thrombotic complications include hypertension, cigarette smoking and diabetes mellitus. Increasing evidence also points to a role of the immune system, as emerging risk factors include inflammation and clonal haematopoiesis. Studies of the cell and molecular biology of atherogenesis have provided considerable insight into the mechanisms that link all these risk factors to atheroma development and the clinical manifestations of this disease. An array of diagnostic techniques, both invasive (such as selective coronary arteriography) and noninvasive (such as blood biomarkers, stress testing, CT and nuclear scanning), permit assessment of cardiovascular disease risk and targeting of therapies. An expanding armamentarium of therapies that can modify risk factors and confer clinical benefit is available; however, we face considerable challenge in providing equitable access to these treatments and in maximizing adherence. Yet, the clinical application of the fruits of research has advanced preventive strategies, enhanced clinical outcomes in affected individuals, and improved their quality of life. Rapidly accelerating knowledge and continued research promise to provide further progress in combating this common chronic disease.
Keywords:
QUALITY-OF-LIFE
CORONARY-ARTERY-DISEASE
CARDIOVASCULAR RISK-FACTORS
DENSITY-LIPOPROTEIN CHOLESTEROL
LEUKOCYTE ADHESION MOLECULE
HUMAN VASCULAR ENDOTHELIUM
SMOOTH-MUSCLE-CELLS
PRIMARY PREVENTION
CLONAL HEMATOPOIESIS
STATIN THERAPY
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
N
IF:
60.6
Papers:
651
Citations:
3.8W
Organization
View more organizations
Cited Papers
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.png)
CIRCULATION
OAAI
CIRCULATIONIF38.6
OAAIShareSaveEfficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsLANCETOAAI
LANCETIF88.5
OAAIShareSave
ShareSaveClinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIERCIRCULATIONOAAI
CIRCULATIONIF38.6
OAAIShareSave View more